Unexpected and perhaps intriguing data from the STAMPEDE trial

In a poster presentation to be given at the upcoming Genitourinary Cancers Symposium in San Francisco later this week, data from the STAMPEDE trial in the UK appear to have demonstrated a result that few people seem to have expected. … READ MORE …

Full data on ADT + chemotherapy from the STAMPEDE trial now published

Back in May 2015, James et al. reported on the survival benefits associated with androgen deprivation therapy (ADT) + docetaxel-based chemotherapy compared to ADT alone as first-line therapy for treatment-naive men initially diagnosed with metastatic prostate cancer. … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer (STAMPEDE trial details)

In a previous commentary, we mentioned the early top-line results of the STAMPEDE trial, which demonstrated a benefit to whole pelvic radiation and ADT for treatment of high-risk prostate cancer when positive pelvic lymph nodes have been detected. We now have some additional details. … READ MORE …

New STAMPEDE data support earlier CHAARTED trial results

So here’s the first important finding that will be presented at the upcoming annual meeting of the American Society for Clinical Oncology (ASCO) annual meeting in Chicago. Data from the UK’s STAMPEDE trial show a significant benefit from combining docetaxel-based chemotherapy with androgen deprivation therapy (ADT) in appropriately selected men. … READ MORE …

Survival of prostate cancer patients diagnosed with M1 disease in the modern era

Back in the late 1980s and early 1990s, the projected survival time for a man diagnosed with evident metastatic prostate cancer (then called D2 disease and now known as TxNxM1 disease) was about 18 to 36 months. Has that really changed in the past 25 years? … READ MORE …

Second-line therapy for progressive, high-risk prostate cancer: time for a STAMPEDE-like trial?

Let’s say you are 58 years of age, in apparently excellent health for your age, when you get diagnosed with high-risk prostate cancer, based on a Gleason score of 4 + 4 = 8, a PSA level of 3.7, and a clinical stage of T1c, with 4/12 biopsy cores positive for cancer. … READ MORE …

An update to the STAMPEDE trial in the UK, Switzerland

We have previously discussed, in some detail,  the multi-arm, ongoing STAMPEDE trial in the UK and Switzerland, which is looking — in a comparative manner — at a whole series of treatment processes among men with advanced forms of prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,367 other followers